HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

Table 8 HIV-1 DNA vs anti-Tat humoral immune responses, adjusted for treatment groups and antiretroviral drug regimens

HIV-1 DNA (log ₁₀ copies/10 ⁶ CD4 ⁺ )	Year ^(a)	Estimate ^(b)	95% CI ^(c)	p value
Anti-Tat humoral response
IgM⁺ and IgG⁺	2^nd	−0.17	−0.28; −0.05	0.0036
	3^rd	−0.26	−0.41; −0.10	0.0012
IgM⁺, IgG⁺ or IgA⁺	2^nd	0.02	−0.08; 0.12	0.3837
	3^rd	−0.17	−0.32; −0.01	0.0356
Ab Negative	2^nd	−0.13	−0.30; 0.04	0.1345
	3^rd	−0.23	−0.46; −0.00	0.0546
Treatment groups
Tat 7.5 μg, 3x	2^nd	−0.01	−0.14; 0.12	0.8997
	3^rd	0.03	−0.18; 0.25	0.7572
Tat 7.5 μg, 5x	2^nd	−0.10	−0.17; 0.03	0.1794
	3^rd	−0.25	−0.43; −0.10	0.0057
Tat 30 μg, 3x	2^nd	−0.16	−0.35; 0.03	0.0975
	3^rd	−0.53	−0.73; −0.33	<0.0001
Tat 30 μg, 5x	2^nd	−0.13	−0.29; 0.02	0.0887
	3^rd	−0.12	−0.31; 0.07	0.2156
Tat 30 μg, 3x vs Tat 7.5 μg, 3x	3^rd	−0.56	−1.02; −0.10	0.0050
Antiretroviral regimens
NNRTI-based or NRTI		−0.05	−0.16; 0.05	0.2971
PI-based		−0.25	−0.36; −0.15	<0.0001
NNRTI-based or NRTI vs PI-based		0.20	0.06; 0.34	0.0047

^(a)Year since first immunization: 48, 72, 84, 96 weeks (2^nd year); 108, 120, 132, 144 weeks (3^rd year); ^(b)Least square means; ^(c)confidence interval.
Multivariate analysis of variance for repeated measures of longitudinal samples from 136 individuals.

ISSN: 1742-4690